Adhoute X, Larrey E, Anty R, Chevallier P, Penaranda G, Tran A, Bronowicki JP, Raoul JL, Castellani P, Perrier H, Bayle O, Monnet O, Pol B, Bourliere M. Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results. World J Clin Cases 2021; 9(18): 4559-4572 [PMID: 34222423 DOI: 10.12998/wjcc.v9.i18.4559]
Corresponding Author of This Article
Xavier Adhoute, Doctor, Department of Gastroenterology and Hepatology, Hôpital Saint-Joseph, 26 Bd de Louvain, Marseille 13008, France. xvadhoute@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
The ALBI score was calculated according to the following equation = 0.66 × log10 bilirubin - 0.085 × albumin (bilirubin level in mcmol/L and albumin level in g/L)
Table 4 Comparison of predictive accuracy for overall survival between pre-/post transarterial chemoembolization-predict and staging/scoring systems in cohort 1 (n = 324)
Scoring/Stage systems
1-yr AUROC
P (vs Ref)
2-yr AUROC
P (vs Ref)
3-yr AUROC
P (vs Ref)
C-index
P (vs Ref)
Pre-TACE-predict
0.67(0.60-0.75)
Ref
0.60(0.56-0.64)
Ref
0.57(0.53-0.60)
Ref
0.59(0.56-0.61)
Ref
“6 and 12” score
0.65(0.56-0.74)
0.6040
0.64(0.58-0.70)
0.1425
0.63(0.57-0.70)
0.0347
0.66(0.58-0.73)
0.0806
BCLC staging
0.60(0.52-0.67)
0.0549
0.64(0.58-0.69)
0.1705
0.61(0.55-0.67)
0.1537
0.61(0.54-0.68)
0.4459
NIACE score
0.77(0.69-0.84)
0.0254
0.69(0.63-0.75)
0.0010
0.69(0.63-0.75)
< 0.0001
0.70(0.64-0.77)
0.0004
Child-Pugh class
0.56(0.49-0.63)
0.0399
0.55(0.51-0.60)
0.1574
0.54(0.49-0.59)
0.4784
0.59(0.55-0.64)
0.8075
ALBI grade
0.63(0.57-0.69)
0.3997
0.56(0.51-0.61)
0.1972
0.55(0.49-0.61)
0.7351
0.62(0.55-0.68)
0.3909
Post-TACE-predict
0.81(0.76-0.87)
Ref
0.73(0.68-0.78)
Ref
0.73(0.67-0.78)
Ref
0.74(0.68-0.80)
Ref
“6 and 12” score
0.65(0.56-0.74)
< 0.0001
0.64(0.58-0.70)
0.0011
0.63(0.57-0.70)
0.0029
0.66(0.58-0.73)
0.0145
BCLC staging
0.60(0.52-0.67)
< 0.0001
0.64(0.58-0.69)
0.0005
0.61(0.55-0.67)
< 0.0001
0.61(0.54-0.68)
0.0002
NIACE score
0.77(0.69-0.84)
0.1673
0.69(0.63-0.75)
0.1263
0.69(0.63-0.75)
0.1927
0.70(0.64-0.77)
0.2562
Child-Pugh class
0.56(0.49-0.63)
< 0.0001
0.55(0.51-0.60)
< 0.0001
0.54(0.49-0.59)
< 0.0001
0.59(0.55-0.64)
< 0.0001
ALBI grade
0.63(0.57-0.69)
< 0.0001
0.56(0.51-0.61)
< 0.0001
0.55(0.49-0.61)
< 0.0001
0.62(0.55-0.68)
0.0051
Table 5 Kaplan-Meier survival analysis according to scores and other systems in cohort 2 (n = 137)
Citation: Adhoute X, Larrey E, Anty R, Chevallier P, Penaranda G, Tran A, Bronowicki JP, Raoul JL, Castellani P, Perrier H, Bayle O, Monnet O, Pol B, Bourliere M. Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results. World J Clin Cases 2021; 9(18): 4559-4572